Cite

HARVARD Citation

    Riudavets, M. et al. (2022). Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. Lung cancer. pp. 255-264. [Online]. 
  
Back to record